Smith Haller J, Straughn J Michael, Buchsbaum Donald J, Arend Rebecca C
Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, United States.
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States.
Gynecol Oncol Rep. 2017 Mar 21;20:81-86. doi: 10.1016/j.gore.2017.03.007. eCollection 2017 May.
Despite a good initial response to chemotherapy, the majority of patients with epithelial ovarian cancer will eventually recur and die of their disease. The introduction of targeted therapies to traditional chemotherapy regimens has done little to improve overall survival in women with ovarian cancer. It has become increasingly apparent that the cancer epigenome contributes significantly to the pathogenesis of ovarian cancer and may play an important role in cell proliferation, metastasis, chemoresistance, and immune tolerance. Epigenetic therapies such as DNA methyltransferase inhibitors and histone deacetylase inhibitors have the potential to reverse these epigenetic changes; however, more research is needed to determine how to incorporate these agents into clinical practice. In this review, we discuss the common epigenetic changes that occur in epithelial ovarian cancer, the current epigenetic therapies that may target these changes, and the clinical experience with epigenetic therapy for the treatment of epithelial ovarian cancer.
尽管上皮性卵巢癌患者最初对化疗反应良好，但大多数患者最终会复发并死于该疾病。在传统化疗方案中引入靶向治疗对改善卵巢癌女性的总体生存率作用不大。越来越明显的是，癌症表观基因组在卵巢癌的发病机制中起重要作用，可能在细胞增殖、转移、化疗耐药和免疫耐受中发挥重要作用。DNA甲基转移酶抑制剂和组蛋白脱乙酰酶抑制剂等表观遗传疗法有可能逆转这些表观遗传变化；然而，需要更多研究来确定如何将这些药物纳入临床实践。在本综述中，我们讨论上皮性卵巢癌中发生的常见表观遗传变化、可能针对这些变化的当前表观遗传疗法，以及表观遗传疗法治疗上皮性卵巢癌的临床经验。
